Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16661429 | 0.84 | — | — | |
| SCHEMBL104766 | 0.77 | COMT (0.32) | NPC1ALDH1A1TP53MAPTPKM | |
| SCHEMBL2600752 | 0.77 | ALDH1A1 (0.31) | NPC1ALDH1A1TP53MAPTPKM | |
| SCHEMBL11957356 | 0.75 | — | — | |
| SCHEMBL17045369 | 0.73 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL18973179 | 0.73 | — | — | |
| SCHEMBL10986635 | 0.73 | FBP1 (0.37) | NPC1MAPTRAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL18647925 | 0.73 | — | — | |
| SCHEMBL18596273 | 0.73 | TLR8 (0.32) | SMN1; SMN2 | |
| SCHEMBL23583864 | 0.71 | GCGR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| US-11634445-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-04-25 | — | — | US | disclosed |
| WO-2020252240-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| US-20200369699-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2020-11-26 | — | — | US | disclosed |
| US-10633386-B2 | BET protein degraders | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190315788-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190169195-A1 | BET PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2019-06-06 | — | — | US | disclosed |
| US-10253044-B2 | 9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-04-09 | — | — | US | disclosed |
| US-20170305894-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Astellas Engineered Small Molecules US, Incorporated | 2017-10-26 | — | — | US | disclosed |
| US-20170305894-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Astellas Engineered Small Molecules US, Incorporated | 2017-10-26 | — | — | US | disclosed |
| US-20090156589-A1 | 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-23 | — | — | US | disclosed |
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090082565-A1 | METHODS OF PREPARING QUINOLONE ANALOGS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20080318939-A1 | METHODS FOR TREATING OPHTHALMIC DISORDERS | CYLENE PHARMACEUTICALS, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080318938-A1 | METHODS FOR TREATING ABERRANT CELL PROLIFERATION DISORDERS | CYLENE PHARMACEUTICALS, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080045526-A1 | HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS | ALLERGAN, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20070293542-A1 | Selective Cox-2 Inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070032652-A1 | Methods of preparing quinolone analogs | SENHWA BIOSCIENCES, INC. (TW) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318939-A1 | METHODS FOR TREATING OPHTHALMIC DISORDERS | EYA3, UACA, ALDH1A2 | NPC1 1062/4885ALDH1A1 273/4885TP53 897/4885 |
| US-20070293542-A1 | Selective Cox-2 Inhibitors | PTGS2, FAAH2, PTGES2 | NPC1 3535/4885ALDH1A1 584/4885TP53 4773/4885 |
| US-20090082565-A1 | METHODS OF PREPARING QUINOLONE ANALOGS | BAX, BAD, MCL1 | NPC1 1678/4885ALDH1A1 2194/4885TP53 6/4885 |
| US-20080045526-A1 | HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS | REN, JAK2, ABL1 | NPC1 4033/4885ALDH1A1 2295/4885TP53 1045/4885 |
| US-20090156589-A1 | 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | CCR10, H1-10, VCAM1 | NPC1 3102/4885ALDH1A1 305/4885TP53 703/4885 |
| US-20080318938-A1 | METHODS FOR TREATING ABERRANT CELL PROLIFERATION DISORDERS | MKI67, PCNA, CCNC | NPC1 1034/4885ALDH1A1 1908/4885TP53 14/4885 |
| US-20200369699-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | L1CAM, EPCAM, SOD1 | NPC1 2857/4885ALDH1A1 853/4885TP53 1963/4885 |
| US-10253044-B2 | 9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors | BRD4, BRD3, BRD1 | NPC1 3924/4885ALDH1A1 981/4885TP53 41/4885 |
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | NPC1 245/4885ALDH1A1 1779/4885TP53 751/4885 |
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | PACSIN2, CKS1B, CSNK1A1 | NPC1 3883/4885ALDH1A1 4513/4885TP53 625/4885 |
| US-20170305894-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARA, PPARD | NPC1 658/4885ALDH1A1 1127/4885TP53 4194/4885 |
| US-20190315788-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | L1CAM, LEF1, ZYX | NPC1 859/4885ALDH1A1 656/4885TP53 2637/4885 |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | PACSIN2, TNKS, PARP1 | NPC1 4479/4885ALDH1A1 3529/4885TP53 494/4885 |
| US-10633386-B2 | BET protein degraders | BRD4, BET1, BRD1 | NPC1 3648/4885ALDH1A1 4006/4885TP53 23/4885 |
| US-20070032652-A1 | Methods of preparing quinolone analogs | BAX, BAD, MCL1 | NPC1 1678/4885ALDH1A1 2194/4885TP53 6/4885 |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | NPC1 325/4885ALDH1A1 3080/4885TP53 937/4885 |
| US-20190169195-A1 | BET PROTEIN DEGRADERS | BRD4, BET1, BRD1 | NPC1 3587/4885ALDH1A1 4023/4885TP53 23/4885 |
| US-11634445-B2 | Organic electroluminescent materials and devices | L1CAM, EPCAM, SOD1 | NPC1 2857/4885ALDH1A1 853/4885TP53 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.